Eli lilly disclaimer

Future Directions of the Treatment of Ovarian Cancer This supplement is based on an Interchange Meeting held in conjunction with the “Summer Conference on Women’s Health Care: Diagnosis, Management & Prevention of Cancer” held in Girdwood, Alaska, August 2002. The material presented herein is intended to be thorough, objective, balanced presentation of GEMZAR (gemcitabine HCI) in a variety of research settings. This sole-sponsored supplement to Gynecologic Oncology is supported by an educational grant from Eli Lilly and Company. The opinions or views expressed in this professional education supplement are those of the authors and do not necessarily reflect the opinions or recommendations of the publisher, guest editors, or Eli Lilly and Company. Lilly provided assistance where necessary to produce the supplement, subject to complete and final editorial control by the authors; no manuscript is being published without the author(s) full knowledge and consent. Lilly was consulted on mauscripts when needed to verify accuracy and/or completeness of scientific information involving Lilly research and with regard to protecting the company’s intellectual property rights. Each manuscript in this supplement was subjected to the publisher’s normal, independent, peer-review process for publication. The articles in this supplement may discuss pharmaceutical products and/or uses of products that have not been approved the US Food and Drug Administration or other regulatory authorities outside the United States. For approved product information consult the manufacturer’s prescribing information or the applicable regulatory authority. Dosages, indications, and methods of use for compounds that are referred to in the supplement by authors may reflect their clinical experience or may be derived from the professional literature or other sources. Because of differences between in vitro and in vivo systems and between laboratory animal models and clinical data in humans, in vitro and animal data may not correlate with clinical results and do not demonstrate clinical safety or efficacy in humans.